Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Norbert Hilf"'
Autor:
Ignacio I Wistuba, Mamta Kalra, Linus Backert, Martin Wermke, Edwin R Parra, Jason John Luke, Apostolia M Tsimberidou, Sebastian Bunk, Mohammad B Hossain, Andrea Mayer-Mokler, Arun Satelli, Norbert Hilf, Steffen Walter, Cedrik M Britten, Van K Morris, Tobias A W Holderried, Winfried H Alsdorf, Katrin Wetzko, Borje S Andersson, Sandra Grund-Gröschke, Katrin Aslan, Anantha Marisetty, Swapna Satam, Jens Hukelmann, M Alper Kursunel, Karine Pozo, Andreas Acs, Melissa Baumeister, Claudia Wagner, Oliver Schoor, Ali S Mohamed, Delfi Krishna
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Rationale of the trial Although the use of engineered T cells in cancer immunotherapy has greatly advanced the treatment of hematological malignancies, reaching meaningful clinical responses in the treatment of solid tumors is still challenging. We i
Externí odkaz:
https://doaj.org/article/6a562891133f4ee084b42c34b2d77b3e
Autor:
Harpreet Singh, Jason Luke, Mamta Kalra, Martin Wermke, Dejka Araujo, Ali Mohamed, Winfried Alsdorf, Apostolia-Maria Tsimberidou, Andrea Mayer-Mokler, Arun Satelli, Carsten Reinhardt, Dominik Maurer, George Jr Blumenschein, Kerstin Guenther, Manik Chatterjee, Norbert Hilf, Regina Mendrzyk, Steffen Walter, Stephen Eck, Tobias AW Holderried, Toni Weinschenk, Van Morris, Cedrik M Britten
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/bc94a9e9c64e462b8ba5414a6783526f
Autor:
Apostolia M. Tsimberidou, Kerstin Guenther, Borje S. Andersson, Regina Mendrzyk, Amir Alpert, Claudia Wagner, Anna Nowak, Katrin Aslan, Arun Satelli, Fabian Richter, Sabrina Kuttruff-Coqui, Oliver Schoor, Jens Fritsche, Zoe Coughlin, Ali S. Mohamed, Kerry Sieger, Becky Norris, Rita Ort, Jennifer Beck, Henry Hiep. Vo, Franziska Hoffgaard, Manuel Ruh, Linus Backert, Ignacio I. Wistuba, David Fuhrmann, Nuhad K. Ibrahim, Van Karlyle. Morris, Bryan K. Kee, Daniel M. Halperin, Graciela M. Nogueras-González, Partow Kebriaei, Elizabeth J. Shpall, David Vining, Patrick Hwu, Harpreet Singh-Jasuja, Carsten Reinhardt, Cedrik M. Britten, Norbert Hilf, Toni Weinschenk, Dominik Maurer, Steffen Walter
Publikováno v:
Cancer Immunology Research.
IMA101 is an actively personalized, multi-targeted adoptive cell therapy (ACT), whereby autologous T cells are directed against multiple novel defined peptide-HLA (pHLA) cancer targets. HLA-A*02:01-positive patients with relapsed/refractory solid tum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d46977681ac8a5cbd10f04dd9e8a6e33
https://doi.org/10.1158/2326-6066.cir-22-0444
https://doi.org/10.1158/2326-6066.cir-22-0444
Autor:
James W.A. Ritchie, Sarah E. Halford, Harpreet Singh-Jasuja, Oliver Schoor, Karen Hill, Jane Peters, Lesley McGuigan, Norbert Hilf, Sarah Kutscher, Juha Lindner, Willie Stewart, Alan Jackson, Sarah Jefferies, Catherine McBain, Christopher J. Twelves, Omar Al-Salihi, Allan James, Paul J. Mulholland, Sharon Peoples, Roy Rampling
Supplementary Table S1. TUMAPs contained in IMA950 and associated source antigens. Supplementary Table S2. Statistical analysis underlying the recruitment of 20 immune evaluable patients per cohort. Supplementary Table S3. Reasons for HLA-A*02 positi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35bb952ed2561cc6de3f0f7698d8e249
https://doi.org/10.1158/1078-0432.22468137.v1
https://doi.org/10.1158/1078-0432.22468137.v1
Autor:
James W.A. Ritchie, Sarah E. Halford, Harpreet Singh-Jasuja, Oliver Schoor, Karen Hill, Jane Peters, Lesley McGuigan, Norbert Hilf, Sarah Kutscher, Juha Lindner, Willie Stewart, Alan Jackson, Sarah Jefferies, Catherine McBain, Christopher J. Twelves, Omar Al-Salihi, Allan James, Paul J. Mulholland, Sharon Peoples, Roy Rampling
Purpose: To perform a two-cohort, phase I safety and immunogenicity study of IMA950 in addition to standard chemoradiotherapy and adjuvant temozolomide in patients with newly diagnosed glioblastoma. IMA950 is a novel glioblastoma-specific therapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24176b5389b980038b76490af7d1161f
https://doi.org/10.1158/1078-0432.c.6526851.v1
https://doi.org/10.1158/1078-0432.c.6526851.v1
Autor:
Harpreet Singh, Christian H. Ottensmeier, Judith R. Kroep, Michael Platten, Andreas von Deimling, Juan Sahuquillo, Eilon Barnea, Cedrik M. Britten, Francisco Martínez-Ricarte, Sebastian Kreiter, Itzhak Rosner, Ghazaleh Tabatabai, Wolfgang Wick, Gleb Slobodin, Hans Skovgaard Poulsen, Sabrina Kuttruff, Sjoerd H. van der Burg, Per thor Straten, Marcos Tatagiba, Dganit Melamed Kadosh, Norbert Hilf, Colette Song, Hans-Georg Rammensee, Frank Winkler, Valérie Dutoit, Ulrik Lassen, Arie Admon, Katrin Frenzel, Pierre-Yves Dietrich, Yael Haimovich, Hideho Okada, Ugur Sahin, Berta Ponsati, Jordi Rodon, John C. Castle, Carlos López-Larrea, Bracha Shraibman
Publikováno v:
Molecular and Cellular Proteomics
Molecular & cellular proteomics : MCP, vol 18, iss 6
Mol Cell Proteomics
Molecular and Cellular Proteomics, Vol. 17, No 11 (2018) pp. 2132-2145
Molecular and Cellular Proteomics, Vol. 18, No 6 (2019) pp. 1255-1268
Molecular and Cellular Proteomics, 17(11), 2132-2145
Molecular & cellular proteomics : MCP, vol 18, iss 6
Mol Cell Proteomics
Molecular and Cellular Proteomics, Vol. 17, No 11 (2018) pp. 2132-2145
Molecular and Cellular Proteomics, Vol. 18, No 6 (2019) pp. 1255-1268
Molecular and Cellular Proteomics, 17(11), 2132-2145
Glioblastoma multiforme (GBM) is the most aggressive brain tumor with poor prognosis to most patients. Immunotherapy of GBM is a potentially beneficial treatment option, whose optimal implementation may depend on familiarity with tumor specific antig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7952a7688b32f085d344d25a5212ed3
https://doi.org/10.1074/mcp.ra119.001524
https://doi.org/10.1074/mcp.ra119.001524
Autor:
Dominik Maurer, Borje S. Andersson, Jens Fritsche, Arun Satelli, Sabrina Kuttruff-Coqui, Kerstin Guenther, Carsten Reinhardt, Steffen Walter, Mamta Kalra, Ali Mohamed, Apostolia Maria Tsimberidou, Rita Ort, Kerry Sieger, Norbert Hilf, Amir Alpert, Anna Nowak, Becky Norris, Toni Weinschenk, David Vining, Oliver Schoor, Fabian Richter, Patrick Hwu, Zoe Coughlin, Cassian Yee, Regina Mendrzyk, Harpreet Singh, Claudia Wagner
Publikováno v:
Regular and young investigator award abstracts.
Background ACTolog (IMA101) is a personalized multi-target adoptive cell therapy (ACT) approach in which autologous T-cell products are redirected against multiple novel defined peptide-HLA (pHLA) cancer targets identified by the target discovery pla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::71a6921cc055df88f8c205a850f3d59f
https://doi.org/10.1136/jitc-2020-sitc2020.0293
https://doi.org/10.1136/jitc-2020-sitc2020.0293
Autor:
Cedrik M. Britten, Regina Mendrzyk, Manik Chatterjee, Tobias A. W. Holderried, Norbert Hilf, Van K. Morris, Andrea Mayer-Mokler, Dominik Maurer, Jason J. Luke, Martin Wermke, Kerstin Guenther, Carsten Reinhardt, Stephen Eck, Dejka M. Araujo, Mamta Kalra, Harpreet Singh, Toni Weinschenk, George Jr Blumenschein, Ali Mohamed, Arun Satelli, Apostolia-Maria Tsimberidou, Winfried Alsdorf, Steffen Walter
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundAdoptive cell therapy demonstrated significant clinical benefit in patients with hematological malignancies but results in most solid tumors have been less encouraging so far.In the IMA203 trial we are treating advanced solid cancer patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d8b12faaba0650449f4486c43b45a06
https://doi.org/10.1136/jitc-2021-sitc2021.959
https://doi.org/10.1136/jitc-2021-sitc2021.959
Autor:
Marij J. P. Welters, Dominik Maurer, Ulrik Lassen, Martin Löwer, Bernhard Rossler, Ugur Sahin, Andreas von Deimling, Toni Weinschenk, Christian H. Ottensmeier, Elisa Rusch, Colette Song, Valérie Dutoit, Jordi Rodon, Norbert Hilf, Hans Skovgaard Poulsen, Nina Pawlowski, Francisco Martínez-Ricarte, Judith R. Kroep, Juan Sahuquillo, Claudia Wagner, Edward W. Green, Sonja Dorner, Cedrik M. Britten, Franziska Hoffgaard, Jens Fritsche, Ghazaleh Tabatabai, Stefan Stevanovic, Harpreet Singh-Jasuja, Marco Skardelly, Sabrina Kuttruff-Coqui, Hans-Georg Rammensee, Katharina Kiesel, Alexander Ulges, Carsten Reinhardt, Michael Platten, Alexandra Kemmer-Brück, Bracha Shraibman, Denis Migliorini, Sebastian Kreiter, Jordi Piro, Oliver Schoor, Valesca Bukur, Katrin Frenzel, Berta Ponsati, David Capper, Jorg Ludwig, Monika Stieglbauer, Regina Mendrzyk, Miriam Meyer, Sjoerd H. van der Burg, Evelyna Derhovanessian, Pierre-Yves Dietrich, Arie Admon, Arbel D. Tadmor, Manja Idorn, Wolfgang Wick, Hideho Okada, Per thor Straten, Sandra Heesch, Lukas Bunse, Christoph Huber, Katy J. McCann, Cécile Gouttefangeas, John C. Castle
Publikováno v:
Nature, 565(7738), 240
Nature, Vol. 565, No 7738 (2019) pp. 240-245
Nature, Vol. 565, No 7738 (2019) pp. 240-245
Patients with glioblastoma currently do not sufficiently benefit from recent breakthroughs in cancer treatment that use checkpoint inhibitors1,2. For treatments using checkpoint inhibitors to be successful, a high mutational load and responses to neo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11b11cf9d2f3e8456103640b3a57a625
https://hdl.handle.net/1887/119498
https://hdl.handle.net/1887/119498
Autor:
Paul Mulholland, Oliver Schoor, Omar Al-Salihi, Chris Twelves, Juha Lindner, Harpreet Singh-Jasuja, Sharon Peoples, Alan Jackson, Sarah Halford, James W A Ritchie, Lesley McGuigan, Catherine McBain, Roy Rampling, Sarah Kutscher, Allan James, Willie Stewart, Norbert Hilf, Jane Peters, Sarah Jefferies, Karen Hill
Publikováno v:
Clinical Cancer Research. 22:4776-4785
Purpose: To perform a two-cohort, phase I safety and immunogenicity study of IMA950 in addition to standard chemoradiotherapy and adjuvant temozolomide in patients with newly diagnosed glioblastoma. IMA950 is a novel glioblastoma-specific therapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33e4ea4b12f63a0322a23115c9d48b3b
https://doi.org/10.1158/1078-0432.ccr-16-0506
https://doi.org/10.1158/1078-0432.ccr-16-0506